Dashboard
Manage Tickers

ETNB89bio, Inc.

Nasdaq 89bio.com


$ 8.72 $ -0.40 (-4.39 %)    

Friday, 10-May-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 8.71
$ 9.06
$ 8.70 x 7,100
$ 8.72 x 400
$ 8.60 - $ 9.11
$ 6.58 - $ 22.93
709,088
na
834.83M
$ 1.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-01-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 03-15-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-24-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 03-18-2020 12-31-2019 10-K
19 12-18-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-89bio-lowers-price-target-to-29
HC Wainwright & Co. Maintains Buy on 89bio...
05/10/2024 12:09:58

HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and lowers the price target from $31 to $29.

89bio-q1-2024-gaap-eps-054-misses-046-estimate
89bio Q1 2024 GAAP EPS $(0.54) Misses $(0....
05/09/2024 21:28:46

89bio (NASDAQ:ETNB) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.46) by 17...

b-of-a-securities-assumes-89bio-at-buy-announces-price-target-of-30
B of A Securities Assumes 89bio at Buy, An...
04/22/2024 10:14:26

B of A Securities analyst Alexandria Hammond assumes 89bio (NASDAQ:ETNB) with a Buy rating and announces Price Target of $30.

on-april-4-2024-89bio-entered-into-collaboration-agreement-with-bibo-biopharma-engineering---filing
On April 4, 2024, 89Bio Entered Into Colla...
04/10/2024 20:35:46

BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, ...

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/05/2024 13:23:32

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

hc-wainwright--co-maintains-buy-on-89bio-maintains-31-price-target
HC Wainwright & Co. Maintains Buy on 89bio...
03/27/2024 17:53:03

HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and maintains $31 price target.

89bio-receives-ema-prime-status-for-pegozafermin-in-the-treatment-of-metabolic-dysfunction-associated-steatohepatitis-with-fibrosis-and-compensated-cirrhosis
89bio Receives EMA PRIME Status For Pegoza...
03/27/2024 12:16:06

–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial ...

hc-wainwright--co-maintains-buy-on-89bio-maintains-31-price-target
HC Wainwright & Co. Maintains Buy on 89bio...
03/13/2024 13:50:31

HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and maintains $31 price target.

89bio-initiates-phase-3-enlighten-fibrosis-trial-of-pegozafermin-in-non-cirrhotic-metabolic-dysfunction-associated-steatohepatitis-patients-with-fibrosis
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis...
03/12/2024 12:02:25

evercore-isi-group-maintains-outperform-on-89bio-raises-price-target-to-37
Evercore ISI Group Maintains Outperform on...
03/07/2024 16:01:25

Evercore ISI Group analyst Liisa Bayko maintains 89bio (NASDAQ:ETNB) with a Outperform and raises the price target from $29 ...

over-20m-bet-on-this-healthcare-stock-check-out-these-3-stocks-insiders-are-buying
Over $20M Bet On This Healthcare Stock? Ch...
03/07/2024 13:54:46

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

evercore-isi-group-maintains-outperform-on-89bio-raises-price-target-to-37
Evercore ISI Group Maintains Outperform on...
03/06/2024 19:00:18

Evercore ISI Group analyst Liisa Bayko maintains 89bio (NASDAQ:ETNB) with a Outperform and raises the price target from $29 ...

oppenheimer-maintains-perform-on-89bioto-perform
Oppenheimer Maintains Perform on 89bioto P...
03/05/2024 12:48:05

Oppenheimer analyst Jay Olson maintains 89bio (NASDAQ:ETNB) from Perform to Perform.

why-bitdeer-technologies-shares-are-trading-higher-by-10-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Bitdeer Technologies Shares Are Tradin...
03/04/2024 18:29:18

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported prelimina...

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
03/04/2024 15:15:53

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
03/04/2024 13:09:46

rbc-capital-maintains-sector-perform-on-89bio-lowers-price-target-to-14
RBC Capital Maintains Sector Perform on 89...
03/01/2024 14:52:14

RBC Capital analyst Brian Abrahams maintains 89bio (NASDAQ:ETNB) with a Sector Perform and lowers the price target from $15 ...

hc-wainwright--co-maintains-buy-on-89bio-lowers-price-target-to-31
HC Wainwright & Co. Maintains Buy on 89bio...
03/01/2024 12:20:50

HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and lowers the price target from $32 to $31.

89bio-q4-eps-050-misses-049-estimate
89bio Q4 EPS $(0.50) Misses $(0.49) Estimate
02/29/2024 21:33:18

89bio (NASDAQ:ETNB) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.49) by 2....

liver-disease-player-89bio-downgraded-analyst-sees-short-term-uncertainties-in-fatty-liver-drug-development
Liver Disease Player 89Bio Downgraded: Ana...
01/12/2024 19:41:51

89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs,...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION